Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

Gil Candel, Mayte; Gascón Cánovas, Juan José; Urbieta Sanz, Elena; Gómez Espín, Rosa; Nicolás de Prado, Isabel; Iniesta Navalón, Carles

INTRODUCTION:

previous studies have shown that higher infliximab trough levels are associated with favorable shortterm and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which patients could benefit from proactive therapeutic drug monitoring in the induction phase. The aim of this study was to evaluate the pharmacokinetic variability of infliximab, determine the factors associated with achieving target infliximab trough levels in the induction phase and analyze the clinical and biochemical response at week 26 of treatment. PATIENTS AND

METHODS:

a retrospective observational study was performed of patients with inflammatory bowel disease and data available on serum levels of infliximab during the induction period. The percentage of patients that achieved target infliximab trough levels at week 6 was determined. Clinical remission and response and biochemical remission were evaluated at week 26.

RESULTS:

thirty patients were included and only 13 (43.3 %) had infliximab trough levels > 15 μg/mL at week 6. A clinical response was observed during the maintenance period in 71.4 % of patients, their infliximab levels were significantly higher than in non-responders (6.3 μg/mL [IQR 6.7] vs 1.0 μg/mL [IQR 5.0], respectively; p = 0.016). Likewise, 53.6 % of patients achieved biochemical remission (responders 6.2 μg/mL [IQR 5.2] vs non-responders 3.2 μg/mL [IQR 5.0]; p = 0.031).

CONCLUSION:

less than half of patients had target infliximab levels during the induction period. Therapeutic drug monitoring during this period is related to the achievement of therapeutic levels of infliximab and may lead to a better clinical response in these patients

Biblioteca Virtual en Salud

Hipertensión

Formato de exportación: